Share This Page
Drugs in ATC Class D11A
✉ Email this page to a colleague
Subclasses in ATC: D11A - OTHER DERMATOLOGICAL PREPARATIONS
D11A Market Analysis and Financial Projection
The market dynamics and patent landscape for ATC Class D11A ("Other Dermatological Preparations") reflect a rapidly evolving sector driven by rising demand for diverse skin treatments and strategic intellectual property (IP) strategies. Below is a detailed analysis:
Market Dynamics
Growth Drivers
- Rising Prevalence of Skin Disorders: Conditions like eczema, acne, psoriasis, and atopic dermatitis are fueling demand for D11A therapies, including antihidrotics, medicated shampoos, and wart treatments [5][11][13]. The global dermatological drugs market is projected to grow at a 10.1% CAGR (2025–2030), driven by innovations in targeted therapies and OTC products [2][7].
- OTC Segment Expansion: Over-the-counter products (e.g., anti-dandruff shampoos, wart removers) are growing due to affordability and accessibility. The OTC segment’s rise is supported by e-commerce platforms and consumer preference for self-care solutions [2][11].
- Technological Advancements: AI-driven drug discovery (e.g., Almirall’s partnership with Microsoft) and novel formulations (e.g., calcineurin inhibitors for eczema) are enhancing treatment efficacy and patient compliance [2][16].
Regional Trends
- Asia-Pacific Dominance: The region is the fastest-growing market (11.7% CAGR) due to improved healthcare infrastructure and awareness of skin health. Countries like China and India are key contributors [2][11].
- U.S. Leadership: The U.S. leads in R&D and commercialization, with therapies like retinoids and minocycline for acne driving growth [13][14].
Challenges
- Regulatory Hurdles: Stringent approval processes and high costs for clinical trials delay market entry [18].
- Economic Barriers: High treatment costs limit access in low-income regions [11].
Patent Landscape
Key Patent Strategies
-
Formulation Innovations: Protection focuses on novel delivery systems (e.g., gels, foams) and stability enhancements. For example:
- Pfizer’s topical formulation (US20230310472A1) for psoriasis/eczema combines hexylene glycol and paraffin wax, excluding butylated hydroxytoluene to reduce irritation [17].
- Arcutis’s roflumilast foam patents emphasize unique pharmacokinetics and extended protection until 2037 [15].
-
Combination Therapies: Patents cover synergistic drug combinations (e.g., retinoids + antibiotics for acne), provided they demonstrate non-obvious benefits [4][16].
-
Dosage and Administration: Claims include optimized dosing regimens (e.g., once-daily tacrolimus creams) and applicator designs (e.g., no-touch dispensers) [4].
Competitive IP Environment
- High-Stakes Litigation: Antibody-related patents face validity challenges, as seen in Centocor v. Abbott ($1.67 billion dispute over Humira®) [3].
- Obviousness Challenges: Formulation patents are vulnerable if prior art suggests similar compositions. Courts favor patents demonstrating unexpected results (e.g., enhanced stability or reduced side effects) [16][4].
Emerging Trends
- Biologics and Immunotherapies: While D11A traditionally excludes biologics, crossover innovations (e.g., anti-inflammatory agents for dermatitis) are entering the space [3][14].
- Personalized Medicine: Patents for patient-specific formulations (e.g., genetic markers for acne susceptibility) are increasing [4][7].
Key Market Players
- Top Companies: Novartis, AbbVie, Galderma, and Johnson & Johnson dominate with portfolios spanning retinoids, calcineurin inhibitors, and medicated shampoos [11][14].
- Recent Launches:
- Zydus Lifesciences’ Minocycline Hydrochloride (acne treatment) [13].
- Eli Lilly’s EBGLYSS (eczema) with 38% efficacy in clinical trials [2].
Future Outlook
- Market Expansion: D11A therapies are projected to benefit from 8.26% CAGR in dermatology (2025–2034), driven by aging populations and aesthetic concerns [11][13].
- Sustainability Focus: Innovations in eco-friendly packaging and preservative-free formulations are emerging as differentiators [4].
Highlight: "Even incremental innovations in dermatology can be patentable if they provide significant benefits over existing treatments." [4]
This sector’s growth hinges on balancing IP protection with addressing unmet medical needs, particularly in emerging markets and underserved conditions.
References
- https://s3.us-east-1.amazonaws.com/prahs-symphony-health/resources/Latam-US-COVID19-Report-April-2020_FINAL.PDF
- https://www.grandviewresearch.com/industry-analysis/dermatological-drugs-market-report
- https://ipwatchdog.com/2017/08/10/immunotherapy-patent-landscape-patent-claims-immunotherapeutic-inventions/id=86634/
- https://patentpc.com/blog/patenting-innovations-dermatological-topical-drugs
- https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=D11A
- https://atcddd.fhi.no/atc_ddd_index/?code=D11AC30
- https://www.globenewswire.com/news-release/2024/02/13/2828489/0/en/Dermatological-Drugs-Market-is-projected-to-grow-at-a-CAGR-10-5-by-2034-Visiongain.html
- https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5065133
- https://www.precedenceresearch.com/air-traffic-control-equipment-market
- http://www.afinitica.com/arnews/sites/default/files/techdocs/Wound%20care%20general%202009.df_.pdf
- https://www.businessresearchinsights.com/market-reports/dermatology-market-118876
- https://www.frontiersin.org/journals/research-metrics-and-analytics/articles/10.3389/frma.2023.978249/full
- https://www.precedenceresearch.com/dermatology-market
- https://www.mordorintelligence.com/industry-reports/dermatological-therapeutics-market
- https://www.arcutis.com/arcutis-expands-patent-portfolio-with-roflumilast-pharmacokinetics-patent/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3857063/
- https://www.pharmaceutical-technology.com/data-insights/pfizer-files-patent-for-topical-formulation-for-treating-inflammatory-disorders/
- https://www.alliedmarketresearch.com/dermatological-drugs-market
More… ↓
